Cardiogenic Shock during First Infusion of Anthracycline Chemotherapy in a Patient with Hodgkin Lymphoma: An Unusual Event
Conclusions: This rare event stresses our inability to correctly predict the risk of a patient developing cardiotoxicity and also highlights the need to improve the knowledge of underlying pathophysiological mechanisms; in fact, it suggests a possible genetic predisposition to develop cardiotoxicity due to a relatively limited dosage.Cardiology 2018;139:7-10
Source: Cardiology - Category: Cardiology Source Type: research
More News: Cancer | Cancer & Oncology | Cardiogenic Shock | Cardiology | Cardiovascular | Chemotherapy | Genetics | Heart | Hodgkin's Disease | Laboratory Medicine | Lymphoma | Septic Shock | Toxicology | Treanda